Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Neoadjuvant radiotherapy followed by surgery can improve overall survival compared with surgery alone in certain patients with locally advanced rectal cancers, most notably in those with lower rectal ...
Efficacy and safety of ponsegromab in patients with colorectal cancer and cachexia: A subgroup analysis of the PROACC-1 phase 2 study. This is an ASCO Meeting Abstract from the 2026 ASCO ...
Patients with localized rectal cancer classified as low risk can skip neoadjuvant chemoradiotherapy (nCRT) with an acceptably low risk of local relapse, new research suggests. A prospective study of ...
Neoadjuvant therapy with immunotherapy in pMMR/MSS rectal cancer shows high response rates and favorable surgical outcomes, with manageable safety profiles. Short-course chemoradiotherapy demonstrates ...
TNT achieved a 93.7% complete response rate and 87.5% organ preservation in stage I rectal cancer patients. TNT may offer an organ-preserving alternative to surgery, especially for low-lying tumors, ...
Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data presented at the 2025 ESMO Congress. Dr. Joshua Sabari, an assistant professor in ...
SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer led to a significant improvement in overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results